Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VISX -- Ignore unavailable to you. Want to Upgrade?

To: Jim Mac who wrote (657)	7/16/1998 4:53:00 PM
From: admr	Read Replies (1) \| Respond to of 1754

I don't know that percentage. What I do know is that the use of the excimer laser in hyperopia is very invasive and has had lots of complications. Snrs just contacted with Omnicom for marketing. It seems to me with the visx stock close to 70 they should buy snrs and lock up the market for hyperopia and presbyopia. A surgeon friend of mine with experience with both lasers says that you have to be out of your mind to use the excimer laser when the LTK process with the Holmium laser is so much easier, cheaper, less invasive with much better results. Snrs I.m told expects to be listed on the Nasdaq soon. The Snrs laser I'm told is about 200,000 dollars also much cheaper for the individual ophthalmogist so they might get better market penetration. Lots of luck any other thought would be appreciated.

To: Jim Mac who wrote (657)	7/17/1998 7:27:00 AM
From: Joe	Read Replies (1) \| Respond to of 1754

It is my understanding that the Sunrise LTK system was designed to and has been used to treat astigmatism, hyperopia with astigmatism, and hyperopia. I think the current clinical trials in the U.S. are only for hyperopia and over-corrected PRK and LASIK. SNRS will no doubt conduct astigmatism trials following approval for hyperopia.

To: Jim Mac who wrote (657)	9/25/1998 2:08:00 PM
From: Charlie Smith	Read Replies (2) \| Respond to of 1754

Jim: Any thoughts on why VISX sued ATCI? VISX Enforces Patent Rights; Autonomous Technologies Corporation Named In Suit Thursday, September 24, 1998 04:14 PM SANTA CLARA, Calif.--(BUSINESS WIRE)--Sept. 24, 1998--VISX, INCORPORATED (Nasdaq NM Symbol: VISX) today announced that it has filed a patent infringement lawsuit in Federal Court in Delaware against Autonomous Technologies Corporation located in Orlando, Florida. The suit is aimed at enforcing VISX's patent rights in the United States relative to the use of ultraviolet lasers to correct vision problems. The patents asserted in the suit are U.S. Patent No. 4,718,418 "Apparatus for Performing Ophthalmic Laser Surgery" and U.S. Patent No. 4,665,913 "Method for Ophthalmological Surgery." VISX is seeking injunctive relief to prevent Autonomous from manufacturing, promoting and selling its infringing equipment in the U.S. In early 1997, Autonomous and VISX entered into a patent license agreement in which VISX granted Autonomous a license to VISX's patents for laser vision correction outside the United States. In return for this license, Autonomous pays royalties to VISX on all sales of their systems worldwide, excluding the U.S. Commenting on this action, Mark B. Logan, Chairman, President and CEO at VISX, said, "VISX pioneered laser vision correction and has spent tens of millions of dollars making this technology available to physicians and their patients. We will enforce our intellectual property rights to protect the investments we and our customers have made, and will continue to make, in this industry." VISX is the worldwide leader in the development of refractive laser technology and has the most extensive patent portfolio in the laser vision correction field. VISX systems are commercially available in the United States and markets worldwide.